Condition: Bronchopulmonary Dysplasia · Chronic Lung Disease of Prematurity · Intraventricular Hemorrhage · Sponsor: OHB Neonatology Ltd.
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
This description comes directly from the study's public registry record.
OHB Contact · CMO@Oakhillbio.com
Always discuss trial participation with your own doctor first.
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Children's Hospital of Orange County | California City, California, United States | Recruiting |
| LAC USC Medical Center | Los Angeles, California, United States | Active Not Recruiting |
| US Davis | Sacramento, California, United States | Recruiting |
| Jackson Memorial Hospital | Miami, Florida, United States | Recruiting |
| Tampa General Hospital | Tampa, Florida, United States | Recruiting |
| University of Illinois at Chicago | Chicago, Illinois, United States | Recruiting |
| Riley Hospital for Children | Indianapolis, Indiana, United States | Recruiting |
| Memorial Hospital of South Bend | South Bend, Indiana, United States | Recruiting |
| Norton Children's Hospital | Louisville, Kentucky, United States | Recruiting |
| Ochsner Baptist Medical Center | New Orleans, Louisiana, United States | Recruiting |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03253263